

# Pierre Van Damme

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6531208/publications.pdf>

Version: 2024-02-01

264  
papers

12,632  
citations

30070

54  
h-index

31849

101  
g-index

280  
all docs

280  
docs citations

280  
times ranked

13988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
3	The global impact of vaccination against hepatitis B: A historical overview. Vaccine, 2008, 26, 6266-6273.	3.8	346
4	Knowledge, Attitudes and Practices in Travel-related Infectious Diseases: The European Airport Survey. Journal of Travel Medicine, 2004, 11, 3-8.	3.0	308
5	Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine, 2009, 27, 454-459.	3.8	285
6	Hepatitis B and the Need for a Booster Dose. Clinical Infectious Diseases, 2011, 53, 68-75.	5.8	246
7	Hepatitis A booster vaccination: is there a need?. Lancet, The, 2003, 362, 1065-1071.	13.7	235
8	Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infectious Diseases, The, 2011, 11, 557-570.	9.1	222
9	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 325-336.	8.1	208
10	Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. Journal of Hepatology, 2018, 68, 167-184.	3.7	194
11	Multicenter Prospective Study of the Burden of Rotavirus Acute Gastroenteritis in Europe, 2004-2005: The REVEAL Study. Journal of Infectious Diseases, 2007, 195, S4-S16.	4.0	181
12	Vaccines and routine immunization strategies during the COVID-19 pandemic. Human Vaccines and Immunotherapeutics, 2021, 17, 400-407.	3.3	165
13	Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. Vaccine, 2016, 34, 142-150.	3.8	147
14	Integration of hepatitis B vaccination into national immunisation programmes. BMJ: British Medical Journal, 1997, 314, 1033-1033.	2.3	128
15	The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet, The, 2019, 394, 148-158.	13.7	123
16	Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host and Microbe, 2020, 27, 736-751.e8.	11.0	118
17	Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine, 2013, 31, 685-690.	3.8	115
18	A review of the long-term protection after hepatitis A and B vaccination. Travel Medicine and Infectious Disease, 2007, 5, 79-84.	3.0	111

#	ARTICLE	IF	CITATIONS
19	Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. <i>Vaccine</i> , 2016, 34, 151-159.	3.8	107
20	Immunogenicity and Safety of a 9-Valent HPV Vaccine. <i>Pediatrics</i> , 2015, 136, e28-e39.	2.1	105
21	Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. <i>Journal of Medical Virology</i> , 2001, 63, 1-7.	5.0	100
22	Distribution of Rotavirus Genotypes in Europe, 2004–2005: The REVEAL Study. <i>Journal of Infectious Diseases</i> , 2007, 195, S17-S25.	4.0	99
23	Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review. <i>PLoS ONE</i> , 2013, 8, e66485.	2.5	97
24	Three decades of hepatitis B control with vaccination. <i>World Journal of Hepatology</i> , 2015, 7, 2127.	2.0	97
25	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27.	3.2	90
26	A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 992-998.	2.0	89
27	Vaccination of healthcare personnel in Europe: Update to current policies. <i>Vaccine</i> , 2019, 37, 7576-7584.	3.8	86
28	Effect of a Prepregnancy Pertussis Booster Dose on Maternal Antibody Titers in Young Infants. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 608-610.	2.0	85
29	AS03<sub>A</sub>–Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age. <i>Clinical Infectious Diseases</i> , 2010, 51, 668-677.	5.8	84
30	Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 2005-2014.	2.9	84
31	Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. <i>Pediatrics</i> , 2016, 138, .	2.1	84
32	Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. <i>Expert Review of Vaccines</i> , 2002, 1, 9-23.	4.4	80
33	Rotavirus Vaccines in Belgium. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, S21-S24.	2.0	79
34	Breastfeeding after maternal immunisation during pregnancy: Providing immunological protection to the newborn: A review. <i>Vaccine</i> , 2014, 32, 1786-1792.	3.8	78
35	The worldwide impact of vaccination on the control and protection of viral hepatitis B. <i>Digestive and Liver Disease</i> , 2011, 43, S2-S7.	0.9	76
36	Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. <i>BMC Infectious Diseases</i> , 2010, 10, 134.	2.9	75

#	ARTICLE	IF	CITATIONS
37	Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. <i>Vaccine</i> , 2016, 34, 3613-3619.	3.8	74
38	Hepatitis B Vaccines. <i>Journal of Infectious Diseases</i> , 2021, 224, S343-S351.	4.0	71
39	A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. <i>Vaccine</i> , 2016, 34, 4205-4212.	3.8	68
40	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. <i>Frontiers in Immunology</i> , 2020, 11, 1282.	4.8	68
41	Long-term antibody persistence after vaccination with a 2-dose Havrix <sup>®</sup> (inactivated hepatitis A) Tj ETQq1 1 0.784314 rgBT / Overlook	3.8	65
42	A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review. <i>BMC Infectious Diseases</i> , 2015, 15, 425.	2.9	64
43	Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. <i>Vaccine</i> , 2007, 25, 4940-4948.	3.8	62
44	Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries. <i>Hum Vaccin</i> , 2011, 7, 734-748.	2.4	62
45	Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. <i>Vaccine</i> , 2014, 32, 1507-1513.	3.8	62
46	Timeliness of infant vaccination and factors related with delay in Flanders, Belgium. <i>Vaccine</i> , 2014, 32, 284-289.	3.8	62
47	Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults. <i>PLoS ONE</i> , 2011, 6, e25398.	2.5	62
48	Immunisation in the current management of cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2005, 4, 77-87.	0.7	61
49	The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam. <i>Clinical Infectious Diseases</i> , 2016, 63, S197-S204.	5.8	60
50	Long-term Protection After Hepatitis B Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 214, 1-3.	4.0	60
51	Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 597-607.	4.0	59
52	Vaccination Coverage in 14-Year-Old Adolescents: Documentation, Timeliness, and Sociodemographic Determinants. <i>Pediatrics</i> , 2008, 121, e428-e434.	2.1	58
53	European Society for Paediatric Infectious Diseases Consensus Recommendations for Rotavirus Vaccination in Europe. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 635-643.	2.0	54
54	Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women. <i>Vaccine</i> , 2015, 33, 4117-4123.	3.8	53

#	ARTICLE	IF	CITATIONS
55	Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, Belgium. <i>Vaccine</i> , 2016, 34, 5785-5791.	3.8	53
56	Cost-effectiveness analysis of hepatitis A prevention in travellers. <i>Vaccine</i> , 1992, 10, S88-S92.	3.8	51
57	Epidemiology of <i>Trichomonas vaginalis</i> and Human Papillomavirus Infection Detected by Real-Time PCR in Flanders. <i>Gynecologic and Obstetric Investigation</i> , 2010, 70, 273-280.	1.6	49
58	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	3.3	49
59	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. <i>Lancet</i> , The, 2021, 397, 39-50.	13.7	49
60	Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. <i>Vaccine</i> , 2011, 29, 4698-4703.	3.8	47
61	Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders. <i>Vaccine</i> , 2018, 36, 6282-6289.	3.8	47
62	Hepatitis B control in Europe by universal vaccination programmes: The situation in 2001. <i>Journal of Medical Virology</i> , 2002, 67, 433-439.	5.0	46
63	12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-13.	3.0	46
64	A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. <i>Expert Review of Vaccines</i> , 2004, 3, 249-267.	4.4	45
65	Vaccination during pregnancy: current and possible future recommendations. <i>European Journal of Pediatrics</i> , 2020, 179, 235-242.	2.7	44
66	Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. <i>Eurosurveillance</i> , 2016, 21, .	7.0	44
67	Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days. <i>Clinical Infectious Diseases</i> , 2019, 68, 607-614.	5.8	43
68	Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2020, 71, 72-80.	5.8	43
69	Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: Long-term follow-up at 15 years. <i>Journal of Medical Virology</i> , 2011, 83, 1885-1891.	5.0	41
70	Overcoming barriers in HPV vaccination and screening programs. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 4, 45-53.	4.5	41
71	Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2012, 30, F1-F11.	3.8	40
72	Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. <i>Vaccine</i> , 2004, 22, 305-308.	3.8	39

#	ARTICLE	IF	CITATIONS
73	Prevention of hepatitis A by Havrix®, a review. Expert Review of Vaccines, 2005, 4, 459-471.	4.4	39
74	Quantification of Vaccine-induced Antipertussis Toxin Secretory IgA Antibodies in Breast Milk. Pediatric Infectious Disease Journal, 2015, 34, e149-e152.	2.0	39
75	A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine, 2016, 34, 5262-5272.	3.8	39
76	Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. International Journal of Cancer, 2016, 139, 518-526.	5.1	38
77	Persistence of antibodies 20Ây after vaccination with a combined hepatitis A and B vaccine. Human Vaccines and Immunotherapeutics, 2017, 13, 972-980.	3.3	38
78	Human papillomavirus detection in urine: Effect of a first-void urine collection device and timing of collection. Journal of Virological Methods, 2019, 264, 23-30.	2.1	38
79	Urine testing for HPV: rationale for using first void. BMJ, The, 2014, 349, g6252-g6252.	6.0	37
80	Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials. Journal of Infectious Diseases, 2018, 217, 1616-1625.	4.0	37
81	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNAâ€Transfected Dendritic Cells. Transplantation, 2015, 99, 120-127.	1.0	36
82	Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine, 2015, 33, 3976-3982.	3.8	36
83	CTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial. Clinical Cancer Research, 2016, 22, 3238-3248.	7.0	34
84	Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100203.	4.5	34
85	Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2021, 21, 286-295.	9.1	34
86	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. Npj Vaccines, 2021, 6, 78.	6.0	34
87	Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy. Pediatric Infectious Disease Journal, 2017, 36, 1186-1192.	2.0	33
88	Exploring the Impact of Exposure to Primary Varicella in Children on Varicella-Zoster Virus Immunity of Parents. Viral Immunology, 2011, 24, 151-157.	1.3	32
89	Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 859-869.	2.9	32
90	Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2018, 96, 484-497.	3.3	32

#	ARTICLE	IF	CITATIONS
91	A global prescription for adult immunization: Time is catching up with us. <i>Vaccine</i> , 2010, 28, 7137-7139.	3.8	31
92	Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in real time: A multi-country analysis for influenza A/H1N1v 2009. <i>Vaccine</i> , 2011, 29, 896-904.	3.8	31
93	An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11-15 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 627-634.	2.0	31
94	Assessing the Evidence for Maternal Pertussis Immunization: A Report From the Bill & Melinda Gates Foundation Symposium on Pertussis Infant Disease Burden in Low- and Lower-Middle-Income Countries. <i>Clinical Infectious Diseases</i> , 2016, 63, S123-S133.	5.8	31
95	Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. <i>Vaccine</i> , 2016, 34, 757-761.	3.8	31
96	Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to <i>Bordetella pertussis</i> antigens in maternal and cord sera of Thai women. <i>Vaccine</i> , 2018, 36, 1453-1459.	3.8	31
97	Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1066-1075.	2.0	31
98	Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium). <i>Vaccine</i> , 2011, 29, 8390-8396.	3.8	30
99	Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. <i>Papillomavirus Research</i> (Amsterdam, Netherlands), 2019, 8, 100185.	4.5	30
100	Safety and immunogenicity of non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine. <i>Vaccine</i> , 2019, 37, 3113-3122.	3.8	30
101	Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020). <i>Vaccine</i> , 2022, 40, 151-161.	3.8	30
102	Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. <i>Vaccine</i> , 2002, 20, 2597-2602.	3.8	29
103	Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2009, 98, 1307-1312.	1.5	29
104	Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial. <i>Vaccine</i> , 2011, 29, 9376-9384.	3.8	29
105	Nasopharyngeal <i>s. pneumoniae</i> carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. <i>Vaccine</i> , 2018, 36, 15-22.	3.8	29
106	Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1496-1519.	3.3	29
107	Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. <i>Current Medical Research and Opinion</i> , 2007, 23, 2729-2739.	1.9	27
108	Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 323-327.	3.3	27



#	ARTICLE	IF	CITATIONS
109	Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine, 2016, 34, 3156-3163.	3.8	27
110	First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 216, 1-11.	1.1	27
111	The effect of maternal antibodies on the cellular immune response after infant vaccination: A review. Vaccine, 2020, 38, 20-28.	3.8	27
112	The health and economic burden of rotavirus disease in Belgium. European Journal of Pediatrics, 2008, 167, 1409-1419.	2.7	26
113	Influence of Frequent Infectious Exposures on General and Varicella-Zoster Virus-Specific Immune Responses in Pediatricians. Vaccine Journal, 2014, 21, 417-426.	3.1	26
114	COVID-19 mortality, excess mortality, deaths per million and infection fatality ratio, Belgium, 9 March 2020 to 28 June 2020. Eurosurveillance, 2022, 27, .	7.0	26
115	Incentives and barriers regarding immunization against influenza and hepatitis of health care workers. Vaccine, 2014, 32, 4849-4854.	3.8	25
116	Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia. Cancer Prevention Research, 2016, 9, 766-771.	1.5	25
117	Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. Journal of Infectious Diseases, 2016, 214, 1498-1506.	4.0	25
118	Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination. Clinical Infectious Diseases, 2019, 69, 797-804.	5.8	24
119	Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. Travel Medicine and Infectious Disease, 2003, 1, 219-226.	3.0	23
120	Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model. BMC Public Health, 2011, 11, 470.	2.9	23
121	Environmental triggers of acute myocardial infarction: results of a nationwide multiple-factorial population study. Acta Cardiologica, 2015, 70, 693-701.	0.9	23
122	Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. Vaccine, 2019, 37, 1080-1086.	3.8	23
123	Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. Vaccine, 2021, 39, 2800-2809.	3.8	23
124	Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. BMC Infectious Diseases, 2010, 10, 357.	2.9	22
125	Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert Opinion on Drug Delivery, 2010, 7, 1109-1125.	5.0	22
126	Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials. Vaccine, 2011, 29, 5932-5939.	3.8	22



#	ARTICLE	IF	CITATIONS
127	Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?. Vaccine, 2012, 30, 2795-2800.	3.8	22
128	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 105-115.	4.5	22
129	Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium. Virulence, 2017, 8, 1245-1254.	4.4	21
130	How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. Eurosurveillance, 2020, 25, .	7.0	21
131	Should Europe have a universal hepatitis B vaccination programme?. BMJ, The, 2013, 347, f4057-f4057.	6.0	20
132	Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. Vaccine, 2014, 32, 3694-3705.	3.8	20
133	Surveillance of effects of HPV vaccination in Belgium. Cancer Epidemiology, 2016, 41, 152-158.	1.9	20
134	Effect of Prepregnancy Pertussis Vaccination in Young Infants. Journal of Infectious Diseases, 2017, 215, 1855-1861.	4.0	19
135	Memory CD4+ T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus. Genes and Immunity, 2019, 20, 255-260.	4.1	19
136	Seroprevalence of IgG antibodies against SARS-CoV-2 – a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. Eurosurveillance, 2022, 27, .	7.0	19
137	Coverage of the expanded program on immunization in Vietnam: Results from 2 cluster surveys and routine reports. Human Vaccines and Immunotherapeutics, 2015, 11, 1526-1533.	3.3	18
138	Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better?. Vaccine, 2018, 36, 2687-2693.	3.8	18
139	From non school-based, co-payment to school-based, free Human Papillomavirus vaccination in Flanders (Belgium): A retrospective cohort study describing vaccination coverage, age-specific coverage and socio-economic inequalities. Vaccine, 2015, 33, 5188-5195.	3.8	17
140	HPV DNA detection in urine samples of women: –an efficacious and accurate alternative to cervical samples?–™. Expert Review of Anti-Infective Therapy, 2019, 17, 755-757.	4.4	17
141	Case-Control Microbiome Study of Chronic Otitis Media with Effusion in Children Points at Streptococcus salivarius as a Pathobiont-Inhibiting Species. MSystems, 2021, 6, .	3.8	17
142	HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV –positive tumour cells. Journal of Cellular and Molecular Medicine, 2014, 18, 1372-1380.	3.6	16
143	Is It Time for Vaccination to –Go Viral–?. Pediatric Infectious Disease Journal, 2016, 35, 1343-1349.	2.0	16
144	Economic Evaluation of Vaccination. Pharmacoeconomics, 1996, 9, 8-15.	3.3	15

#	ARTICLE	IF	CITATIONS
145	Modelling forces of infection by using monotone local polynomials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2003, 52, 469-485.	1.0	15
146	Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing. <i>International Journal of Molecular Sciences</i> , 2016, 17, 750.	4.1	15
147	Triage of human papillomavirus infected women by methylation analysis in first-void urine. <i>Scientific Reports</i> , 2021, 11, 7862.	3.3	15
148	One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. <i>Vaccine</i> , 2022, 40, 196-205.	3.8	15
149	Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3746-3753.	3.3	14
150	Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria, 2010–2011. <i>Journal of Medical Virology</i> , 2015, 87, 401-406.	5.0	14
151	Prevalence of high-risk human papillomavirus and abnormal pap smears in female sex workers compared to the general population in Antwerp, Belgium. <i>BMC Public Health</i> , 2016, 16, 477.	2.9	14
152	First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. <i>Journal of Clinical Virology</i> , 2019, 117, 11-18.	3.1	14
153	Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country. <i>Contemporary Clinical Trials</i> , 2020, 99, 106189.	1.8	14
154	Can COVID-19 symptoms as reported in a large-scale online survey be used to optimise spatial predictions of COVID-19 incidence risk in Belgium?. <i>Spatial and Spatio-temporal Epidemiology</i> , 2020, 35, 100379.	1.7	14
155	In-depth analysis of pneumococcal serotypes in Belgian children (2015–2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease. <i>Vaccine</i> , 2021, 39, 372-379.	3.8	14
156	Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. <i>Npj Vaccines</i> , 2021, 6, 94.	6.0	14
157	Assessing vaccination coverage in infants, survey studies versus the Flemish immunisation register: Achieving the best of both worlds. <i>Vaccine</i> , 2014, 32, 345-349.	3.8	13
158	Long-term Antibody Persistence in Children After Vaccination With the Pediatric Formulation of an Aluminum-free Virosomal Hepatitis A Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e85-e91.	2.0	13
159	Herpes zoster is associated with herpes simplex and other infections in under 60 year-olds. <i>Journal of Infection</i> , 2015, 70, 171-177.	3.3	13
160	Hepatitis B Vaccines. , 2018, , 342-374.e17.		13
161	HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?. <i>International Journal of Infectious Diseases</i> , 2019, 88, 110-112.	3.3	13
162	mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 799-803.	0.7	13

#	ARTICLE	IF	CITATIONS
163	Response to diphtheria booster vaccination in healthy adults: vaccine trial. <i>BMJ: British Medical Journal</i> , 2000, 320, 217-217.	2.3	12
164	Immune Memory and Immune Response in Children From Bulgaria 5â€“15 Years After Primary Hepatitis B Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 51-53.	2.0	12
165	Should female sex workers be offered HPV vaccination?. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1544-1548.	3.3	12
166	Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. <i>Annals of Global Health</i> , 2020, 86, 81.	2.0	12
167	Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results. <i>Journal of Infectious Diseases</i> , 2022, 226, 119-127.	4.0	12
168	Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1566-1575.	0.7	12
169	Safety and Immunogenicity of a Highâ€“Potency Inactivated Hepatitis A Vaccine. <i>Journal of Travel Medicine</i> , 1996, 3, 83-90.	3.0	11
170	Long-term persistence of humoral and cellular immune responses induced by an AS03<sub>A</sub>-adjuvanted H1N1 2009 influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1512-1522.	3.3	11
171	The use of urine in the follow-up of HPV vaccine trials. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 350-352.	3.3	11
172	Assessment of the timely administration of the hepatitis B and BCG birth dose and the primary infant vaccination schedule in 2015â€“2016 in the Mekong Delta, Viet Nam. <i>Vaccine</i> , 2018, 36, 5760-5765.	3.8	11
173	Poliopolis: pushing boundaries of scientific innovations for disease eradication. <i>Future Microbiology</i> , 2019, 14, 1321-1330.	2.0	11
174	Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol. <i>BMJ Open</i> , 2021, 11, e046835.	1.9	11
175	Preexisting memory CD4 T cells in naÃ“ve individuals confer robust immunity upon hepatitis B vaccination. <i>ELife</i> , 2022, 11, .	6.0	11
176	Repeated-measures models to evaluate a hepatitis B vaccination programme. <i>Statistics in Medicine</i> , 2001, 20, 951-963.	1.6	10
177	Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). <i>BMC Pediatrics</i> , 2010, 10, 42.	1.7	10
178	HPV immunization programs: Ensuring their sustainability and resilience. <i>Vaccine</i> , 2018, 36, 5219-5221.	3.8	10
179	Diagnosing enterovirus meningitis via blood transcriptomics: an alternative for lumbar puncture?. <i>Journal of Translational Medicine</i> , 2019, 17, 282.	4.4	10
180	Impact of Collection Volume and DNA Extraction Method on the Detection of Biomarkers and HPV DNA in First-Void Urine. <i>Molecules</i> , 2021, 26, 1989.	3.8	10

#	ARTICLE	IF	CITATIONS
181	Cost Effectiveness of Alternative Hepatitis A Immunisation Strategies. <i>Pharmacoeconomics</i> , 1995, 8, 5-8.	3.3	9
182	An Economic Evaluation of Hepatitis A Vaccination in Dutch Military Personnel. <i>Military Medicine</i> , 1998, 163, 564-567.	0.8	9
183	Strategies for Global Prevention of Hepatitis B Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2010, 659, 175-188.	1.6	9
184	Long-term Immunogenicity and Immune Memory After Two Doses of the Adult Formulation of a Combined Hepatitis A and B Vaccine in Children 1 to 11 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 703-705.	2.0	9
185	Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN- $\gamma$ in patients with relapsing-remitting multiple sclerosis. <i>Innate Immunity</i> , 2016, 22, 266-273.	2.4	9
186	Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1800-1806.	3.3	9
187	An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix. <i>Vaccine</i> , 2019, 37, 2537-2553.	3.8	9
188	SARS-CoV-2 seroprevalence survey among health care providers in a Belgian public multiple-site hospital. <i>Epidemiology and Infection</i> , 2021, 149, e172.	2.1	9
189	SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1755-1757.	1.8	9
190	Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report. <i>BMC Proceedings</i> , 2021, 15, 16.	1.6	9
191	Environmental triggers of acute myocardial infarction: results of a nationwide multiple-factorial population study. <i>Acta Cardiologica</i> , 2015, 70, 693-701.	0.9	9
192	CAREGIVERS' WILLINGNESS TO PAY TO REDUCE THE NUMBER OF VACCINE INJECTIONS IN INFANTS. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 61-63.	2.0	8
193	Reduced Prevalence of HBsAg Variants following a Successful Immunization Program in China. <i>Journal of Virology</i> , 2014, 88, 4605-4606.	3.4	8
194	Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	8
195	A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. <i>Vaccine</i> , 2017, 35, 6700-6706.	3.8	8
196	Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity. <i>Immunogenetics</i> , 2018, 70, 363-372.	2.4	8
197	Comparison of a VLP-based and GST $\pi$ -based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first void urine. <i>Journal of Medical Virology</i> , 2020, 92, 3774-3783.	5.0	8
198	Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium. <i>Family Practice</i> , 2022, 39, 92-98.	1.9	8

#	ARTICLE	IF	CITATIONS
199	Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e28573.	4.3	8
200	Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	7.0	8
201	Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol. <i>BMJ Open</i> , 2022, 12, e054688.	1.9	8
202	Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium. <i>Vaccine</i> , 2015, 33, 3026-3034.	3.8	7
203	Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly. <i>Viral Immunology</i> , 2016, 29, 169-175.	1.3	7
204	Recruitment barriers for prophylactic vaccine trials: A study in Belgium. <i>Vaccine</i> , 2017, 35, 6598-6603.	3.8	7
205	Poliopolis. <i>Lancet, The</i> , 2019, 394, 115.	13.7	7
206	Clinical trials with GMO-containing vaccines in Europe: Status and regulatory framework. <i>Vaccine</i> , 2019, 37, 6144-6153.	3.8	7
207	Low adherence with national travel medicine recommendations in Belgian expatriate children: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2019, 32, 101424.	3.0	7
208	Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. <i>Vaccine</i> , 2020, 38, 3227-3234.	3.8	7
209	Many European countries 'flying blind' in their efforts to eliminate viral hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 445-446.	17.8	6
210	Hospital-wide SARS-CoV-2 antibody screening of staff in a university psychiatric centre in Belgium. <i>BJPsych Open</i> , 2021, 7, e40.	0.7	6
211	Efficacy of Influenza Immunisation Programmes Comparison of Two European Systems in One Practice. <i>European Journal of General Practice</i> , 2002, 8, 159-162.	2.0	5
212	Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults. <i>Journal of Medical Virology</i> , 2009, 81, 1710-1715.	5.0	5
213	Estimating vaccination coverage for the trivalent measles-mumps-rubella vaccine from trivariate serological data. <i>Statistics in Medicine</i> , 2012, 31, 1432-1449.	1.6	5
214	Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: A Phase I dose escalating study in healthy volunteers. <i>Vaccine</i> , 2014, 32, 5118-5124.	3.8	5
215	Commentary to: Guide to tailoring immunization programmes in the WHO European Region. <i>Vaccine</i> , 2015, 33, 4385-4386.	3.8	5
216	Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. <i>Vaccine</i> , 2020, 38, 6914-6921.	3.8	5

#	ARTICLE	IF	CITATIONS
217	Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine. <i>Frontiers in Immunology</i> , 2020, 11, 1657.	4.8	5
218	A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3710-3728.	3.3	5
219	Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. <i>Journal of Medical Virology</i> , 2001, 63, 1-7.	5.0	5
220	Evolving measles status and immunization policy development in six European countries. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-15.	3.3	5
221	Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned. <i>Vaccine</i> , 2022, 40, 3470-3480.	3.8	5
222	Estimation of the Force of Infection from Current Status Data Using Generalized Linear Mixed Models. <i>Journal of Applied Statistics</i> , 2007, 34, 923-939.	1.3	4
223	The introduction of policies for human papillomavirus vaccination in Europe. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2008, 16, 291-298.	1.6	4
224	LESSONS LEARNED FROM A MEASLES OUTBREAK IN ANTWERP, BELGIUM. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 343-345.	2.0	4
225	Zoster in Monasteries: Some Clarification Needed. <i>Clinical Infectious Diseases</i> , 2012, 54, 305-306.	5.8	4
226	Two decades of hepatitis B vaccination in mentally retarded patients: Effectiveness, antibody persistence and duration of immune memory. <i>Vaccine</i> , 2012, 30, 4757-4761.	3.8	4
227	Multi-disease analysis of maternal antibody decay using non-linear mixed models accounting for censoring. <i>Statistics in Medicine</i> , 2015, 34, 2858-2871.	1.6	4
228	Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium. <i>Medicine (United States)</i> , 2019, 98, e15412.	1.0	4
229	Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium. <i>PLoS ONE</i> , 2020, 15, e0234740.	2.5	4
230	Stable HEV IgG seroprevalence in Belgium between 2006 and 2014. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1253-1260.	2.0	4
231	Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. <i>Vaccine</i> , 2020, 38, 1643-1651.	3.8	4
232	The Fifth International Neonatal and Maternal Immunization Symposium (INMIS 2019): Securing Protection for the Next Generation. <i>MSphere</i> , 2021, 6, .	2.9	4
233	Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: Double-blind, randomised, controlled phase 2 trial. <i>Liver International</i> , 2021, 41, 2318-2327.	3.9	4
234	Algorithm for the support of non-related (serious) adverse events in an Ebola vaccine trial in the Democratic Republic of the Congo. <i>BMJ Global Health</i> , 2021, 6, e005726.	4.7	4



#	ARTICLE	IF	CITATIONS
235	Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. , 2001, 63, 1.		4
236	Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium. Journal of Infectious Diseases, 2020, , .	4.0	4
237	Legal and illegal drug use among female sex workers in bar and club prostitution in Belgium: A quantitative and qualitative study. Drugs: Education, Prevention and Policy, 2014, 21, 56-64.	1.3	3
238	Hepatitis A Vaccines. , 2017, , 99-108.		3
239	Knowledge about HIV in People with Schizophrenia: A General Population Comparison. Clinical Schizophrenia and Related Psychoses, 2011, 5, 80-86.	1.4	3
240	Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors?? Reply. Pharmacoeconomics, 2004, 22, 136-138.	3.3	2
241	What counts in cytometric analysis to document vaccine immunogenicity?. Human Vaccines and Immunotherapeutics, 2012, 8, 499-500.	3.3	2
242	Elucidating the difference in the kinetics of antibody titres of infants in Belgium and Vietnam. Vaccine, 2020, 38, 7079-7086.	3.8	2
243	“Alternative abridged preventive regimens against rabies for children in high endemic countries”™. Vaccine, 2020, 38, 5578-5579.	3.8	2
244	Sampling Site Matters When Counting Lymphocyte Subpopulations. PLoS ONE, 2012, 7, e41405.	2.5	2
245	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. PLoS ONE, 2016, 11, e0165384.	2.5	2
246	Replacing vaccine paper package inserts: a multi-country questionnaire study on the acceptability of an electronic replacement in different target groups. BMC Public Health, 2022, 22, 156.	2.9	2
247	Detection of SARS-CoV-2 in young children attending day-care centres in Belgium, May 2020 to February 2022. Eurosurveillance, 2022, 27, .	7.0	2
248	Combined Two-Dose Hepatitis A and B Vaccine (AmBirix??*). Drugs, 2003, 63, 214-215.	10.9	1
249	Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?” Human Vaccines and Immunotherapeutics, 2016, 12, 2053-2056.	3.3	1
250	A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. Future Microbiology, 2019, 14, 369-372.	2.0	1
251	Letter to the editor: female sex workers and HPV vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 126-127.	3.3	1
252	Transcriptomic profiling of different responder types in adults after a Priorix® vaccination. Vaccine, 2020, 38, 3218-3226.	3.8	1



#	ARTICLE	IF	CITATIONS
253	The influenza vaccine for nursing and care professionals at emergency services in Flanders. Human Vaccines and Immunotherapeutics, 2021, 17, 2719-2722.	3.3	1
254	Hepatitis B vaccination among GPs in Flanders, Belgium in 1999. European Journal of General Practice, 2001, 7, 77-78.	2.0	0
255	Nieuwe vaccins. Bijblijven (Amsterdam, Netherlands), 2015, 31, 535-554.	0.0	0
256	Re: Letter to the Editor: P. van Damme et al., Vaccine 34 (2016) 757â€“761, as a reply to Ryser et al.'s letter in Vaccine. Vaccine, 2016, 34, 4272.	3.8	0
257	Enrolment of young women attending cervical cancer screening to survey effectiveness of HPV vaccination. Cancer Epidemiology, 2016, 45, 178-179.	1.9	0
258	Hepatitis A Vaccines. , 2021, , 115-125.		0
259	Hepatitis B Vaccines. , 2017, , 109-116.		0
260	Long-term protection after hepatitis A and B vaccination: an update. Acta Gastro-Enterologica Belgica, 2003, 66, 247-9.	1.0	0
261	Title is missing!. , 2020, 15, e0234740.		0
262	Title is missing!. , 2020, 15, e0234740.		0
263	Title is missing!. , 2020, 15, e0234740.		0
264	Title is missing!. , 2020, 15, e0234740.		0